July 20, 2022 – Japanese Nissan Chemical: Iptriazopyrid – New Herbicide Candidate Published. The Japanese player filed their international patent covering Iptriazopyrid…
admin
-
-
RegulatoryU.S FDA
FDA Approved ZONISADE™ (Zonisamide Oral Suspension) of AZURITY PHARMACEUTICALS, INC.
by adminby adminSummary : The first and only FDA-approved zonisamide oral liquid formulation 100 mg/5 mL as adjunctive therapy for the treatment of partial…
-
RegulatoryU.S FDA
The U.S. FDA has Approved Opzelura(Ruxolitinib) Cream by Incyte for the Treatment of Vitiligo.
by adminby adminSynopsis : Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show…
-
Summary : GSK plc announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on…
-
Global MarketRegulatoryU.S FDA
Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)
by adminby adminSummary : Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it…
-
RegulatoryU.S FDA
The FDA Designated PT886 from Phanes Therapeutics as an Orphan Drug for the Treatment of Pancreatic Cancer.
by adminby adminSynopsis : The U.S. Food and Medication Administration (FDA) has designated PT886 as an orphan drug for the treatment of pancreatic cancer,…
-
Global MarketRegulatoryU.S FDA
Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
by adminby adminSummary : First and only nitric oxide generator and delivery system indicated for the treatment of termand near-term neonates with hypoxic respiratory…
-
IndiaPatent Litigation
Panacea Biotec Files Suit against Sanofi for Patent Infringement for EasySix Vaccine
by adminby adminSummary : Panacea Biotec on Monday said it has filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare…
-
Bristol Myers SquibbRegulatoryU.S FDA
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi®(lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
by adminby adminSynopsis: In the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median…
-
Insecticide Resistance Action Committee (IRAC)Resistance Action Committee (RAC)
Insecticide Resistance Action Committee (IRAC) – Published New Mode of Action Classification – Now including Nematicides 2022
by adminby adminInsecticide Resistance Action Committee (IRAC) – Published New Mode of Action Classification – Now including Nematicides 2022 The Insecticide Resistance Action Committee…
